Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

por Andtbacka, Robert H. I., Collichio, Frances, Harrington, Kevin J., Middleton, Mark R., Downey, Gerald, Ӧhrling, Katarina, Kaufman, Howard L.
Publicado 2019